This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Ointment in Patients With Psoriasis Vulgaris

This study has been completed.
Information provided by:
LEO Pharma Identifier:
First received: November 3, 2005
Last updated: February 20, 2008
Last verified: February 2008
This study will evaluate the efficacy and safety of calcipotriol plus betamethasone dipropionate ointment compared with calcipotriol ointment in the treatment of patients with psoriasis vulgaris for a duration of 4 weeks. The study will focus on the percentage change of the psoriasis area and severity index (PASI) from baseline to the end of week 4.

Condition Intervention Phase
Psoriasis Vulgaris Drug: Calcipotriol plus betamethasone dipropionate ointment Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris

Resource links provided by NLM:

Further study details as provided by LEO Pharma:

Primary Outcome Measures:
  • The percentage change of PASI at the end of week 4 compared with baseline

Secondary Outcome Measures:
  • The change of PASI at the end of week 4 compared with baseline
  • The change of Dermatology Life Quality Index at the end of week 4 compared with baseline
  • Physician's Global Assessment at the end of week 4
  • Patient's assessment by Visual Analogue Scale (VAS) at the end of week 4
  • The change of individual scores of redness, thickness, and scaliness at the end of week 4 on the target lesion compared with baseline
  • The change of overall lesion area percentage (scalp and face area excluded) at the end of week 4 compared with baseline

Estimated Enrollment: 320
Study Start Date: October 2005
Estimated Study Completion Date: February 2006

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of psoriasis vulgaris in a stable condition
  • Extent of at least 10% of one or more body regions
  • Amenable to topical therapy with maximum of 100 g/week of investigational product

Exclusion Criteria:

  • Patients with more than 30% of body surface area involved
  • Patients with facial psoriasis who need treatment
  • Patients who need treatment of scalp psoriasis with WHO group IV topical corticosteroids, tretinoin or topical vitamin D derivatives
  • Patients with unstable forms of psoriasis including guttate, erythrodermic, pustular, or arthritis psoriasis
  • Systemic treatment of psoriasis with corticosteroids or other therapy
  • Systemic antipsoriatic treatment (e.g. corticosteroids, immunosuppressive drugs, tretinoin, antibiotics, phototherapy or calcium agents) within 4 weeks prior to visit 1; or topical antipsoriatic treatment (e.g. keratolytics, topical corticosteroids, topical vitamin D derivatives, anthralin, crude coal tar, etc) within the previous 2 week period
  • Patients with planned exposure to phototherapy that may affect the psoriasis during the study period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00248456

Fudan University First Hospital, Dermatology Department
Shanghai, China, 200040
Sponsors and Collaborators
LEO Pharma
Principal Investigator: Zheng Zhi Zhong, Professor Fudan University First Hospital, Dermatology Department
  More Information Identifier: NCT00248456     History of Changes
Other Study ID Numbers: EX 0501 CN
Study First Received: November 3, 2005
Last Updated: February 20, 2008

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases
Betamethasone benzoate
Betamethasone Valerate
Betamethasone sodium phosphate
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Growth Substances
Bone Density Conservation Agents processed this record on September 21, 2017